PharmaCyte Biotech, Inc. has announced a reverse stock split of its common stock at a ratio of 1-for-19. This decision, effective November 12, 2026, aims to increase the company's stock price and improve its market appeal. The move comes as part of the company's broader strategy to enhance shareholder value.

PharmaCyte Biotech, based in Las Vegas, Nevada, operates in the biological products sector, specifically focusing on biological products without diagnostic substances. The company trades under the ticker symbol PMCB on the Nasdaq exchange. The reverse stock split was approved by stockholders during the annual meeting held on March 30, 2026, where 68.96% voted in favor of the proposal.

According to the filing dated November 13, 2026, every nineteen shares of the company's common stock will be combined into one share, with proportionate adjustments made to stock options, warrants, and convertible securities. The filing states, "The Common Stock began trading on a split-adjusted basis at the open of trading on The Nasdaq Capital Market on November 13, 2026." Additionally, any fractional shares resulting from the split will be compensated with cash payments based on the closing sales price prior to the effective date.

The impact of this reverse stock split may affect existing shareholders, as their holdings will be consolidated. The company aims to attract more institutional investors and improve its overall market perception. This move may also influence other companies in the biological products industry, potentially prompting them to consider similar actions to enhance their stock performance.

Following this announcement, PharmaCyte Biotech is expected to continue its operational strategies while monitoring the market response to the reverse stock split. The filing does not specify any immediate next steps beyond this adjustment.